PTC Therapeutics Q3 2019 Earnings Report

Total Revenue
$71.4M
Previous year: $53.6M
+33.3%
EPS
-$1.06
Previous year: -$1.06
+0.0%
R&D Expenses
$63.1M
SG&A Expenses
$49.3M
Cash, cash equivalents
$687M

PTC Therapeutics

PTC Therapeutics

PTC Therapeutics Revenue by Segment